Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 10/20 | 0.48 |
| ▸ | OGA | O60502 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.43 |
| ▸ | ATR | Q13535 | 1/20 | 0.41 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14554006 | 0.90 | SORD (0.51) | SORDOGAKMT2AMEN1USP2 | |
| SCHEMBL14553999 | 0.84 | SORD (0.54) | SORDOGAKMT2AMEN1USP2 | |
| SCHEMBL3640716 | 0.83 | HRH3 (0.52) | SORDUSP2ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL2616799 | 0.81 | SORD (0.51) | SORDHRH4 | |
| SCHEMBL28125284 | 0.80 | HRH4 (0.63) | SORDUSP2ALDH1A1CYP1A2ALOX15 | |
| SCHEMBL6224825 | 0.79 | HRH3 (0.54) | SORDUSP2ALDH1A1CYP1A2HSD17B10 | |
| SCHEMBL14525065 | 0.79 | SORD (0.49) | SORDHRH4 | |
| SCHEMBL27693708 | 0.78 | SORD (0.54) | SORDOGAKMT2AMEN1USP2 | |
| SCHEMBL4724828 | 0.78 | SORD (0.78) | SORD | |
| SCHEMBL3665897 | 0.78 | KMT2A (0.42) | KMT2AALDH1A1CYP1A2TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090149458-A1 | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS | WYETH (US) | 2009-06-11 | — | — | US | disclosed |
| WO-2009070524-A1 | PYRROLO[3,2-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND MTOR KINASE INHIBITORS | WYETH (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149458-A1 | PYRROLO[3,2-d]PYRIMIDINE COMPOUNDS AND THEIR USE AS PI3 KINASE AND mTOR KINASE INHIBITORS | MTOR, PIK3CA, PIK3CD | SORD 1255/4885OGA 4507/4885KMT2A 2655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.